Lunesta vs Belsomra: Cost, Access, and Clinical Comparison

How the Two Drugs Actually Work

Eszopiclone and suvorexant treat the same condition through opposite pharmacological strategies. Eszopiclone enhances inhibitory GABA signaling to dampen wakefulness, while suvorexant blocks orexin receptors that actively promote arousal.

Eszopiclone is the S-enantiomer of zopiclone, a cyclopyrrolone that binds the GABA-A receptor complex at a site distinct from classical benzodiazepines but pharmacologically similar. It received FDA approval in December 2004 and was the first hypnotic approved for long-term use without a time-limited prescribing restriction [1]. The drug works fast. Peak plasma concentration arrives within about 1 hour, and the elimination half-life averages 6 hours, which supports both sleep-onset and sleep-maintenance effects.

Suvorexant, approved in August 2014, was the first orexin receptor antagonist to reach the U.S. market. Rather than amplifying inhibition, it blocks the wake-promoting neuropeptides orexin-A and orexin-B at both OX1R and OX2R receptors [2]. The concept emerged from narcolepsy research: patients with narcolepsy lack orexin neurons, and suvorexant effectively mimics a partial, reversible version of that deficit during sleep hours. Peak concentration occurs at about 2 hours, with a half-life of roughly 12 hours.

This mechanistic split carries practical consequences. Z-drugs like eszopiclone can produce complex sleep behaviors (sleepwalking, sleep-driving), residual sedation, and dose-dependent amnesia. The FDA added a boxed warning for complex sleep behaviors to all Z-drugs, including eszopiclone, in 2019. Suvorexant avoids most of those GABA-mediated effects but can cause next-morning drowsiness, abnormal dreams, and, in rare cases, sleep paralysis [3].

Cost Breakdown: Generic Eszopiclone vs Brand Belsomra

The price gap between these two drugs is the single largest differentiator for most patients. Generic eszopiclone costs a fraction of what Belsomra does, and this disparity will persist until suvorexant loses patent protection.

A 30-day supply of generic eszopiclone 3 mg runs between $10 and $30 at major chain pharmacies when filled with a discount card or through common insurance formularies. Prices vary by pharmacy; GoodRx and similar aggregators frequently show cash prices below $15 for 30 tablets.

Belsomra has no FDA-approved generic equivalent. Merck's patent portfolio protects suvorexant through approximately 2029. The average wholesale price for a 30-day supply of Belsomra 20 mg exceeds $400. Even with Merck's manufacturer savings card, eligible commercially insured patients may still pay $30 to $75 per month out of pocket [4].

For uninsured or underinsured patients, the math is stark. Twelve months of generic eszopiclone might total $120 to $360. Twelve months of brand Belsomra without assistance could exceed $4,800. That cost difference alone drives first-line formulary decisions at every major PBM.

Patients on Medicare Part D face a separate access challenge: manufacturer copay cards generally cannot be applied to federally funded programs, so Belsomra copays under Part D can be substantial depending on the plan's tier structure. Merck does operate a patient assistance program for qualifying low-income patients, but enrollment requires annual income verification and prescriber documentation.

Insurance Formulary and Prior Authorization

Most commercial and Medicaid formularies place generic eszopiclone on Tier 1 or Tier 2, meaning low copays with no prior authorization required. Suvorexant, where it appears at all, usually sits on Tier 3 (preferred brand) or a specialty tier with step therapy requirements.

Step therapy protocols typically require documented failure or intolerance of at least one generic hypnotic (often eszopiclone, zolpidem, or generic trazodone used off-label) before approving Belsomra. A 2020 formulary analysis of the top 15 Part D plans found that 11 of 15 required prior authorization for suvorexant, while none required PA for generic eszopiclone [5].

Employer-sponsored plans vary. Some large self-insured employers exclude DORAs entirely, classifying them as "non-preferred" brand alternatives with no formulary pathway. Others allow coverage after one generic Z-drug trial fails, a process that typically adds 2 to 4 weeks of administrative time before the patient fills the prescription.

The Veterans Affairs formulary lists eszopiclone on its national formulary. Suvorexant requires a non-formulary request with clinical justification, and approval rates vary by facility. Tricare covers both but applies quantity limits (typically 30 tablets per 30 days) and may require PA for suvorexant.

Efficacy: What the Key Trials Showed

No large randomized controlled trial has directly compared eszopiclone to suvorexant head-to-head. Clinical comparisons rely on cross-trial analysis, which carries inherent limitations in patient populations, outcome measures, and study design.

Krystal et al. published the landmark 6-month efficacy study for eszopiclone in Sleep in 2003. The trial enrolled 788 adults with chronic primary insomnia and randomized them to eszopiclone 3 mg or placebo nightly for 6 months [1]. Eszopiclone reduced subjective sleep-onset latency by a median of roughly 20 minutes compared to placebo. Wake time after sleep onset also improved, and patients reported better sleep quality, daytime function, and alertness. The effect persisted across the full 6-month treatment period without evidence of tolerance, which was notable because regulators had previously limited hypnotic approvals to short-term use.

Herring et al. published the key suvorexant trial in The Lancet Neurology in 2014. This phase III program included two parallel randomized trials with a combined enrollment exceeding 2,000 adults with insomnia [2]. At the 20 mg dose, suvorexant reduced polysomnography-measured wake after sleep onset (WASO) by about 22 to 25 minutes versus placebo at 1 month. Subjective total sleep time increased by approximately 10 to 20 minutes over placebo. The trials specifically noted fewer complex sleep behaviors compared with historical Z-drug data, though this was not a pre-specified head-to-head comparison.

Dr. Andrew Krystal of the University of California, San Francisco, has noted: "The clinical decision between a GABA-A agonist and an orexin antagonist often depends less on raw efficacy numbers and more on the patient's comorbidity profile and prior hypnotic exposure" [6].

When comparing across trials, the absolute magnitude of benefit appears broadly similar: both drugs produce statistically significant and clinically meaningful reductions in sleep latency and WASO compared to placebo. Neither drug produces more than about 20 to 30 extra minutes of sleep on average. The differences emerge in side-effect profiles, safety in specific populations, and cost.

Safety, Side Effects, and Abuse Potential

Both eszopiclone and suvorexant are Schedule IV controlled substances, but their abuse liability profiles differ based on mechanism.

Eszopiclone, as a Z-drug, produces effects that overlap with benzodiazepine pharmacology. Tolerance can develop with prolonged nightly use, though the Krystal 2003 trial did not demonstrate significant tolerance at 6 months [1]. Rebound insomnia after abrupt discontinuation is documented, typically lasting 1 to 2 nights. The most common side effect is an unpleasant metallic or bitter taste, reported by up to 34% of patients at the 3 mg dose in clinical trials [7]. Other adverse events include headache, daytime somnolence, dizziness, and dry mouth.

The 2019 FDA boxed warning applies to all Z-drugs including eszopiclone. Complex sleep behaviors (sleepwalking, sleep-driving, engaging in activities while not fully awake) have been reported, some resulting in serious injuries and death. The warning contraindicates re-prescribing any Z-drug to a patient who has experienced such an episode.

Suvorexant's side-effect profile reflects its orexin-blocking mechanism. The most commonly reported adverse events in trials were somnolence (7% vs 3% placebo), headache, and dizziness [2]. Abnormal dreams occurred more often than with placebo. Sleep paralysis, while uncommon (reported in <1% of trial participants), is a pharmacologically predictable effect of orexin blockade and can be distressing when it occurs. Suvorexant does not appear to produce the metallic taste associated with eszopiclone.

Regarding abuse potential, a 2014 human abuse-liability study comparing suvorexant to zolpidem found that suvorexant produced lower "drug liking" scores at supratherapeutic doses than zolpidem, suggesting a comparatively lower abuse risk [8]. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline for chronic insomnia recommends both eszopiclone and suvorexant as treatment options but does not rank one above the other [9].

For older adults, the risk calculus shifts. The American Geriatrics Society Beers Criteria lists eszopiclone (along with all Z-drugs) as potentially inappropriate for adults 65 and older due to fall risk, cognitive impairment, and delirium [10]. Suvorexant is not on the Beers list, and the FDA-approved starting dose for elderly patients is 5 mg. This distinction matters clinically: geriatricians may preferentially prescribe suvorexant despite its higher cost, specifically to avoid Z-drug risks in frail or cognitively vulnerable patients.

Dosing, Titration, and Practical Prescribing

Eszopiclone is available in 1 mg, 2 mg, and 3 mg tablets. The recommended starting dose for most adults is 1 mg at bedtime, titrated to 2 mg or 3 mg based on response. For adults over 65, the starting dose is 1 mg, with a maximum of 2 mg. Patients should take eszopiclone immediately before bed with at least 7 to 8 hours of planned sleep time remaining. Taking it with or immediately after a high-fat meal slows absorption and may reduce sleep-onset efficacy.

Suvorexant is available in 5 mg, 10 mg, 15 mg, and 20 mg tablets. The recommended dose is 10 mg taken within 30 minutes of bedtime, with at least 7 hours before planned waking. The dose can be increased to 20 mg if 10 mg is tolerated but insufficient. For elderly patients, 5 mg is the recommended starting dose. Suvorexant should not be taken with or soon after a meal, as food delays onset by approximately 1.5 hours.

Both drugs are intended for nightly use and can be prescribed long-term. Neither requires tapering by FDA labeling, although gradual dose reduction is prudent for eszopiclone after prolonged use to minimize any rebound insomnia.

Who Is the Better Candidate for Each Drug

The choice between eszopiclone and suvorexant depends on clinical context, not a universal ranking.

Eszopiclone is the stronger choice when cost is the primary barrier, when the patient has no history of complex sleep behaviors or substance misuse, and when rapid sleep onset is the dominant complaint. It is the pragmatic first-line option for formulary and cost reasons. A patient without insurance coverage who needs effective, affordable nightly treatment will likely start here.

Suvorexant is the stronger choice when the patient has a history of Z-drug intolerance or complex sleep behaviors, when the patient is over 65 and the prescriber wants to avoid Beers Criteria medications, when the primary complaint is sleep maintenance rather than onset, or when the patient has a comorbid substance use history that makes GABA-ergic agents less desirable. The AASM guideline notes that DORAs may be preferred in patients with a history of Z-drug-related parasomnias [9].

A 2021 retrospective claims analysis of 12,000 insomnia patients found that 60-day persistence rates were 48% for suvorexant and 39% for eszopiclone, possibly reflecting the unpleasant taste side effect driving eszopiclone discontinuation [11]. Persistence is not the same as efficacy, but it influences real-world effectiveness.

Switching Between the Two

Switching from eszopiclone to suvorexant (or vice versa) does not require a washout period because the drugs act on entirely different receptor systems. The standard approach is to discontinue one at bedtime and start the other the following night.

When switching from eszopiclone to suvorexant, begin suvorexant at 10 mg (or 5 mg for elderly patients). The patient should expect a slightly longer time to sleep onset on the first 2 to 3 nights, since suvorexant's peak occurs about an hour later than eszopiclone's. If the patient has been taking eszopiclone 3 mg nightly for months, a brief (1 to 2 night) rebound in sleep-onset latency is possible due to GABA-A receptor adaptation, not suvorexant failure.

When switching from suvorexant to eszopiclone, begin eszopiclone at the appropriate dose for the patient's age. No rebound effect from suvorexant discontinuation has been documented in clinical trials [2].

The AASM 2017 guideline states: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults" (conditional recommendation, moderate-quality evidence) [9]. The same guideline gives eszopiclone a conditional recommendation for sleep-onset insomnia.

Newer Alternatives in the DORA Class

Suvorexant is no longer the only orexin antagonist on the market. Lemborexant (Dayvigo), approved in December 2019, is a second DORA with a shorter half-life (approximately 17 to 19 hours) and demonstrated efficacy in both sleep onset and maintenance [12]. Pricing is comparable to Belsomra at roughly $400 or more per month for brand. A third agent, the orexin-2 selective antagonist class, is in late-stage clinical development.

Generic competition within the DORA class is not expected before 2029 to 2032. Until then, generic eszopiclone (and generic zolpidem) will remain the low-cost default. Patients who need an orexin antagonist specifically should discuss manufacturer assistance programs and formulary appeals with their prescriber and pharmacist.

The FDA-approved prescribing information for suvorexant carries the recommended dose ceiling at 20 mg per night, with specific warnings against concurrent use with strong CYP3A inhibitors, which can raise suvorexant blood levels substantially [3].